Introduction / Definition
Atrioventricular Nodal Reentrant Tachycardia (AVNRT) is the most prevalent form of supraventricular tachycardia (SVT). This paroxysmal arrhythmia characteristically manifests in individuals with structurally normal hearts and exhibits a slight epidemiological predominance in females. Episodes typically present with an abrupt onset in the absence of an identifiable precipitating factor, presenting with a ventricular rate ranging between 130 and 220 beats per minute (bpm). Pharmacological termination via intravenous intervention in a hospital setting may be required. Although the initial clinical manifestation can occur at any age, it predominantly presents during the third to fifth decades of life (30–50 years).
Pathophysiology / Mechanism
Patients with AVNRT possess dual nodal pathways within their cardiac conduction system: a fast pathway and a slow pathway, both converging at the atrioventricular (AV) node. Under normal conditions (sinus rhythm), the electrical impulse propagates through both pathways to reach the AV node, subsequently proceeding through the Bundle of His, the bundle branches (right and left), the Purkinje fibers, and ultimately the ventricular myocardium.
Under certain conditions, however, a reentrant circuit (reentry loop) is established between the fast and slow pathways, sustaining rapid micro-reentry within the AV nodal region. As the impulse exits this circuit, it propagates simultaneously via two fronts:
- Retrogradely toward the atria.
- Anterogradely via the physiological conduction pathway toward the ventricles, thereby driving an elevated ventricular rate typically between 130 and 220 bpm.
Clinical Presentation / Symptoms
AVNRT episodes are characterized by a paroxysmal nature, featuring sudden onset and abrupt termination, occurring either spontaneously or via medical intervention. The symptomatic spectrum aligns with that of other supraventricular tachycardias and includes:
- Palpitations: Frequently perceived in the cervical/neck region (a critical diagnostic feature differentiating it from other tachycardias), resulting from retrograde blood flow caused by the simultaneous, uncoordinated contraction of the atria and ventricles.
- Dyspnea (shortness of breath).
- Reduced fatigue tolerance / exercise intolerance.
- Chest discomfort / thoracic distress.
- Asthenia (generalized weakness).
- Dizziness / lightheadedness.
- Diaphoresis (profuse sweating).
- Urinary frequency (polyuria).
- Syncope or presyncope (fainting), presenting in rarer instances.
Etiology
AVNRT occurs in individuals with a structurally normal myocardium and stems from the aforementioned reentrant circuit involving dual nodal pathways. The precise congenital or developmental mechanism detailing why individuals born with dual pathways remain asymptomatic until mid-life is not yet fully elucidated. Furthermore, electrophysiological studies demonstrate that a subset of the population possesses dual nodal pathways without ever developing clinical AVNRT. While episodes generally occur spontaneously, a high density of premature contractions (ectopic beats) may serve as the mechanical trigger to initiate the circular propagation of the impulse within the reentrant circuit.
Diagnosis
The primary diagnostic modality for AVNRT is electrocardiography (ECG). An ECG recorded during an acute paroxysmal episode demonstrates high diagnostic accuracy and is definitive for AVNRT. In cases where the arrhythmia has not been captured on a standard ECG but the clinical history is highly suggestive, intensive ambulatory ECG monitoring is indicated if episodes are frequent. Alternatively, the patient should be instructed to seek immediate ECG recording at the onset of a symptomatic episode. If diagnostic ambiguity persists despite these measures and clinical suspicion remains high, an electrophysiological study (EPS) is indicated, which also provides the opportunity for concurrent definitive treatment via catheter ablation.
Prognosis
AVNRT is not a life-threatening arrhythmia. However, it causes a significant burden on patient quality of life, as episodes often fail to self-terminate, necessitating emergency department admission for pharmacological cardioversion. Catheter ablation offers a permanent and definitive cure, eliminating the need for subsequent therapeutic interventions.
Although inherently benign, the coexistence of AVNRT with other acute cardiac or extracardiac conditions can lead to clinical complications. For instance, the onset of AVNRT during pregnancy poses distinct therapeutic challenges, as pharmacological options are strictly constrained due to potential teratogenic or adverse fetal effects. Even intravenous adenosine, the first-line agent of choice for acute termination, carries a risk of adverse events. Consequently, definitive prophylactic treatment with catheter ablation should be strongly recommended to young women planning a future pregnancy.
Therapeutic Management
Therapeutic management is classified into acute interventions for immediate termination of an episode and long-term prophylactic strategies.
Acute Management
Immediate termination of a reentrant paroxysmal episode can be attempted via vagal maneuvers (such as the Valsalva maneuver, bearing down, coughing, etc.) or carotid sinus massage. If the episode persists, hospital evaluation is required for the administration of intravenous first-line agents, most commonly adenosine or verapamil. Acute pharmacological termination is less readily achieved using oral medications, though beta-blockers or non-dihydropyridine calcium channel blockers (verapamil, diltiazem) may be utilized.
Prophylactic & Long-Term Management
Long-term prophylactic management to prevent recurrent episodes depends entirely on the frequency of events and the severity of clinical symptoms.
- Pharmacological Prophylaxis: Maintenance therapy may be prescribed to reduce recurrence. First-line agents include beta-blockers and calcium channel blockers (verapamil, diltiazem), while class I or III antiarrhythmic drugs (propafenone, flecainide, sotalol, amiodarone) are reserved for rarer, refractory cases. Continuous, long-term pharmacological therapy can induce side effects such as bradycardia or asthenia, which are frequently poorly tolerated by young and active patients. Furthermore, long-term antiarrhythmic agents carry proarrhythmic risks and systemic adverse reactions that may be significantly more severe than AVNRT itself.
- Catheter Ablation: This is considered the treatment of choice for the majority of patients, as it offers a permanent, definitive cure. The primary risk associated with the procedure is inadvertent injury to the atrioventricular node, potentially leading to atrioventricular (AV) block. If a high-degree or complete symptomatic AV block occurs, permanent cardiac pacemaker implantation is required. Statistically, historical and contemporary literature estimates this risk at approximately 0.5%. However, in experienced electrophysiology centers, the probability is significantly lower—virtually negligible—and should not deter patients from choosing a definitive cure for this disruptive clinical condition.
Figure Captions
- Figure 1: Baseline ECG recording demonstrating normal sinus rhythm followed by the abrupt onset of atrioventricular nodal reentrant tachycardia (AVNRT).
- Figure 2: The Valsalva maneuver.